Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party

Mohamad Sobh, M. Michallet, G. Gahrton, S. Iacobelli, A. van Biezen, Stefan Schönland, E. Petersen, N. Schaap, F Bonifazi, L. Volin, E Meijer, D. Niederwieser, J. el Cheikh, Reza Tabrizi, N Fegeux, J. Finke, D Bunjes, J.J. Cornelissen, H. Einsele, B. Bruno & 5 others M.N. Potter, R Fanin, M. Mohty, L. Garderet, Nicolaus Kröger

Research output: Contribution to journalArticleAcademic

Abstract

We describe the use and outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for multiple myeloma (MM) in Europe between January 1990 and December 2012. We identified 7333 patients, median age at allo-HSCT was 51 years (range: 18-78), of whom 4539 (62%) were males. We distinguished three groups: (1) allo-HSCT upfront (n=1924), (2) tandem auto-allo-HSCT (n=2004) and (3) allo-HSCT as a second line treatment and beyond (n=3405). Overall, there is a steady increase in numbers of allo-HSCT over the years. Upfront allo-HSCT use increased up to year 2000, followed by a decrease thereafter and represented 12% of allo-HSCTs performed in 2012. Tandem auto-allo-HSCT peaked around year 2004 and contributed to 19% of allo-HSCTs in 2012. Allo-HSCT as salvage after one or two or three autografts was steadily increasing over the last years and represented 69% of allo-HSCTs in 2012. Remarkable heterogeneity in using allo-HSCT was observed among the different European countries. The 5-year survival probabilities from time of allo-HSCT for the three groups after year 2004 were 42%, 54% and 32%, respectively. These results show that the use of allo-HSCT is increasing in Europe, especially as second line treatment and beyond. There is an unmet need for well-designed prospective studies investigating allo-HSCT as salvage therapy for MM.

Original languageEnglish
Pages (from-to)2047-2054
Number of pages8
JournalLeukemia
Volume30
Issue number10
DOIs
Publication statusPublished - Oct 2016

Cite this

Sobh, Mohamad ; Michallet, M. ; Gahrton, G. ; Iacobelli, S. ; van Biezen, A. ; Schönland, Stefan ; Petersen, E. ; Schaap, N. ; Bonifazi, F ; Volin, L. ; Meijer, E ; Niederwieser, D. ; el Cheikh, J. ; Tabrizi, Reza ; Fegeux, N ; Finke, J. ; Bunjes, D ; Cornelissen, J.J. ; Einsele, H. ; Bruno, B. ; Potter, M.N. ; Fanin, R ; Mohty, M. ; Garderet, L. ; Kröger, Nicolaus. / Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe : trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. In: Leukemia. 2016 ; Vol. 30, No. 10. pp. 2047-2054.
@article{5fec15c23a9a42ff9f0d57a932e258c0,
title = "Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party",
abstract = "We describe the use and outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for multiple myeloma (MM) in Europe between January 1990 and December 2012. We identified 7333 patients, median age at allo-HSCT was 51 years (range: 18-78), of whom 4539 (62{\%}) were males. We distinguished three groups: (1) allo-HSCT upfront (n=1924), (2) tandem auto-allo-HSCT (n=2004) and (3) allo-HSCT as a second line treatment and beyond (n=3405). Overall, there is a steady increase in numbers of allo-HSCT over the years. Upfront allo-HSCT use increased up to year 2000, followed by a decrease thereafter and represented 12{\%} of allo-HSCTs performed in 2012. Tandem auto-allo-HSCT peaked around year 2004 and contributed to 19{\%} of allo-HSCTs in 2012. Allo-HSCT as salvage after one or two or three autografts was steadily increasing over the last years and represented 69{\%} of allo-HSCTs in 2012. Remarkable heterogeneity in using allo-HSCT was observed among the different European countries. The 5-year survival probabilities from time of allo-HSCT for the three groups after year 2004 were 42{\%}, 54{\%} and 32{\%}, respectively. These results show that the use of allo-HSCT is increasing in Europe, especially as second line treatment and beyond. There is an unmet need for well-designed prospective studies investigating allo-HSCT as salvage therapy for MM.",
keywords = "Journal Article",
author = "Mohamad Sobh and M. Michallet and G. Gahrton and S. Iacobelli and {van Biezen}, A. and Stefan Sch{\"o}nland and E. Petersen and N. Schaap and F Bonifazi and L. Volin and E Meijer and D. Niederwieser and {el Cheikh}, J. and Reza Tabrizi and N Fegeux and J. Finke and D Bunjes and J.J. Cornelissen and H. Einsele and B. Bruno and M.N. Potter and R Fanin and M. Mohty and L. Garderet and Nicolaus Kr{\"o}ger",
year = "2016",
month = "10",
doi = "10.1038/leu.2016.101",
language = "English",
volume = "30",
pages = "2047--2054",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "10",

}

Sobh, M, Michallet, M, Gahrton, G, Iacobelli, S, van Biezen, A, Schönland, S, Petersen, E, Schaap, N, Bonifazi, F, Volin, L, Meijer, E, Niederwieser, D, el Cheikh, J, Tabrizi, R, Fegeux, N, Finke, J, Bunjes, D, Cornelissen, JJ, Einsele, H, Bruno, B, Potter, MN, Fanin, R, Mohty, M, Garderet, L & Kröger, N 2016, 'Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party' Leukemia, vol. 30, no. 10, pp. 2047-2054. https://doi.org/10.1038/leu.2016.101

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe : trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. / Sobh, Mohamad; Michallet, M.; Gahrton, G.; Iacobelli, S.; van Biezen, A.; Schönland, Stefan; Petersen, E.; Schaap, N.; Bonifazi, F; Volin, L.; Meijer, E; Niederwieser, D.; el Cheikh, J.; Tabrizi, Reza; Fegeux, N; Finke, J.; Bunjes, D; Cornelissen, J.J.; Einsele, H.; Bruno, B.; Potter, M.N.; Fanin, R; Mohty, M.; Garderet, L.; Kröger, Nicolaus.

In: Leukemia, Vol. 30, No. 10, 10.2016, p. 2047-2054.

Research output: Contribution to journalArticleAcademic

TY - JOUR

T1 - Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe

T2 - trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party

AU - Sobh, Mohamad

AU - Michallet, M.

AU - Gahrton, G.

AU - Iacobelli, S.

AU - van Biezen, A.

AU - Schönland, Stefan

AU - Petersen, E.

AU - Schaap, N.

AU - Bonifazi, F

AU - Volin, L.

AU - Meijer, E

AU - Niederwieser, D.

AU - el Cheikh, J.

AU - Tabrizi, Reza

AU - Fegeux, N

AU - Finke, J.

AU - Bunjes, D

AU - Cornelissen, J.J.

AU - Einsele, H.

AU - Bruno, B.

AU - Potter, M.N.

AU - Fanin, R

AU - Mohty, M.

AU - Garderet, L.

AU - Kröger, Nicolaus

PY - 2016/10

Y1 - 2016/10

N2 - We describe the use and outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for multiple myeloma (MM) in Europe between January 1990 and December 2012. We identified 7333 patients, median age at allo-HSCT was 51 years (range: 18-78), of whom 4539 (62%) were males. We distinguished three groups: (1) allo-HSCT upfront (n=1924), (2) tandem auto-allo-HSCT (n=2004) and (3) allo-HSCT as a second line treatment and beyond (n=3405). Overall, there is a steady increase in numbers of allo-HSCT over the years. Upfront allo-HSCT use increased up to year 2000, followed by a decrease thereafter and represented 12% of allo-HSCTs performed in 2012. Tandem auto-allo-HSCT peaked around year 2004 and contributed to 19% of allo-HSCTs in 2012. Allo-HSCT as salvage after one or two or three autografts was steadily increasing over the last years and represented 69% of allo-HSCTs in 2012. Remarkable heterogeneity in using allo-HSCT was observed among the different European countries. The 5-year survival probabilities from time of allo-HSCT for the three groups after year 2004 were 42%, 54% and 32%, respectively. These results show that the use of allo-HSCT is increasing in Europe, especially as second line treatment and beyond. There is an unmet need for well-designed prospective studies investigating allo-HSCT as salvage therapy for MM.

AB - We describe the use and outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for multiple myeloma (MM) in Europe between January 1990 and December 2012. We identified 7333 patients, median age at allo-HSCT was 51 years (range: 18-78), of whom 4539 (62%) were males. We distinguished three groups: (1) allo-HSCT upfront (n=1924), (2) tandem auto-allo-HSCT (n=2004) and (3) allo-HSCT as a second line treatment and beyond (n=3405). Overall, there is a steady increase in numbers of allo-HSCT over the years. Upfront allo-HSCT use increased up to year 2000, followed by a decrease thereafter and represented 12% of allo-HSCTs performed in 2012. Tandem auto-allo-HSCT peaked around year 2004 and contributed to 19% of allo-HSCTs in 2012. Allo-HSCT as salvage after one or two or three autografts was steadily increasing over the last years and represented 69% of allo-HSCTs in 2012. Remarkable heterogeneity in using allo-HSCT was observed among the different European countries. The 5-year survival probabilities from time of allo-HSCT for the three groups after year 2004 were 42%, 54% and 32%, respectively. These results show that the use of allo-HSCT is increasing in Europe, especially as second line treatment and beyond. There is an unmet need for well-designed prospective studies investigating allo-HSCT as salvage therapy for MM.

KW - Journal Article

U2 - 10.1038/leu.2016.101

DO - 10.1038/leu.2016.101

M3 - Article

VL - 30

SP - 2047

EP - 2054

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 10

ER -